Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

Presentation TCT 2024

TCT 585: Impella CP and 5.5 Device Flows Are Overestimated by the SmartAssist Automated Impella Controller (AIC)

Presenter: Christian Said

October 30, 2024

Presentation TCT 2024

TCT 262: Clinical and Hemodynamic Predictors of Stabilization and Associated Complications in Cardiogenic Shock Patients Supported With Impella 5.5

Presenter: Shashank Sinha

October 29, 2024

Presentation TCT 2024

Debate Pro: Keep P8 Impella 5.5 (de-escalate VA) as Bridge to Recovery

Presenter: Amirali Masoumi

October 29, 2024

Presentation TCT 2024

TCT 582: Evaluation of LVEDP Change During High-Risk PCI With and Without Impella Support (ELVIS): A Pilot Trial

Presenter: Juergen Leick

October 28, 2024

Presentation TCT 2024

TCT 576: The Impact of Atherectomy in Severely Calcified Lesions in Patients With Impella-Supported High-Risk Percutaneous Coronary Intervention: Insights From the cVAD PROTECT III Study

Presenter: Batla Falah

October 28, 2024

Presentation THT 2024

Introduction Of Guideline Directed Medical Therapy And Native Heart Recovery In Patients Supported By Impella 5.5

Presenter: Kanika P. Mody

March 06, 2024

Presentation THT Abstracts 2024

Outcomes of Impella 5.5 in Heart Failure-Related Cardiogenic Shock from the SURPASS (Surgical Unloading Renal Protection and Sustainable Support) Registry

Presenter: Jacob Abraham

March 05, 2024

Presentation THT Abstracts 2024

Clinical Outcomes and Adverse Events in Cardiogenic Shock Patients who Recieved Impella 5.0/5.5: A Report from the Cardiogenic Shock Working Group

Presenter: Justin Fried

March 05, 2024

Presentation THT Abstracts 2024

A Report from the Cardiogenic Shock Working Group on use of Impella 5.0/5.5 for Cardiogenic Shock and Successful Bridge to Recovery, durable LVAD or Heart Transplantation

Presenter: Maryjane Farr

March 05, 2024

Presentation THT 2024

Clinical Outcomes and Adverse Events in Cardiogenic Shock Patients who Recieved Impella 5.0/5.5: A Report from the Cardiogenic Shock Working Group

Presenter: Justin Fried

March 05, 2024

Presentation THT Abstracts 2024

Enhanced Cardiac Support and Reduced Risks: Evaluating Impella 5.5 in ECPELLA Therapy

Presenter: Ameesh Isath

March 04, 2024

Presentation THT Abstracts 2024

Assessment of patients with cardiogenic shock requiring veno-arterial extracorporeal membrane oxygenation upgrade from Impella 5.5 univentricular support

Presenter: James Schurr

March 04, 2024

Presentation CTO Plus 2024 Abstracts On-Demand 2024

Mechanical Circulatory Support for High-Risk Percutaneous Coronary Intervention with Impella CP versus Impella 5.5

Presenter: Samip Vasaiwala

February 02, 2024

Advertisement

TCT 585: Impella CP and 5.5 Device Flows Are Overestimated by the SmartAssist Automated Impella Controller (AIC)

TCT 262: Clinical and Hemodynamic Predictors of Stabilization and Associated Complications in Cardiogenic Shock Patients Supported With Impella 5.5

Debate Pro: Keep P8 Impella 5.5 (de-escalate VA) as Bridge to Recovery

TCT 582: Evaluation of LVEDP Change During High-Risk PCI With and Without Impella Support (ELVIS): A Pilot Trial

TCT 576: The Impact of Atherectomy in Severely Calcified Lesions in Patients With Impella-Supported High-Risk Percutaneous Coronary Intervention: Insights From the cVAD PROTECT III Study

Introduction Of Guideline Directed Medical Therapy And Native Heart Recovery In Patients Supported By Impella 5.5

Outcomes of Impella 5.5 in Heart Failure-Related Cardiogenic Shock from the SURPASS (Surgical Unloading Renal Protection and Sustainable Support) Registry

Clinical Outcomes and Adverse Events in Cardiogenic Shock Patients who Recieved Impella 5.0/5.5: A Report from the Cardiogenic Shock Working Group

A Report from the Cardiogenic Shock Working Group on use of Impella 5.0/5.5 for Cardiogenic Shock and Successful Bridge to Recovery, durable LVAD or Heart Transplantation

Clinical Outcomes and Adverse Events in Cardiogenic Shock Patients who Recieved Impella 5.0/5.5: A Report from the Cardiogenic Shock Working Group

Enhanced Cardiac Support and Reduced Risks: Evaluating Impella 5.5 in ECPELLA Therapy

Assessment of patients with cardiogenic shock requiring veno-arterial extracorporeal membrane oxygenation upgrade from Impella 5.5 univentricular support

Mechanical Circulatory Support for High-Risk Percutaneous Coronary Intervention with Impella CP versus Impella 5.5

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content